Small molecule · developed by Organon and Co
E6005 (also known as RVT-501) is a topical ointment studied in atopic dermatitis, applied at concentrations from 0.01% to 0.2%.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02094235 | Phase 1/2 | Atopic Dermatitis | Completed | OGN |
| NCT01179880 | Phase 1/2 | Atopic Dermatitis | Completed | OGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atopic Dermatitis
Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.
See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OGN catalysts and pipeline →